Ventrus Biosciences reports PK and safety data for VEN 307

Ventrus Biosciences (VTUS) says two clinical dermal safety studies of VEN 307 demonstrate the treatment is safe and well tolerated.

No serious AE's were reported.

All pharmacokinetic parameters were met in a separate study, consistent with an earlier investigator sponsored trial.

The data "mark another important step in [the] effort to develop and commercialize [the drug]," CEO Russell Ellison says.

VEN 307 is currently in a second pivotal Phase 3 trial. (PR)

Shares +12% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs